Search

Displaying results 2421 - 2430 of 2743 in total
  1. Drug

    Risvodetinib

    go.drugbank.com/drugs/DB21602
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Risvodetinib is a tyrosine kinase inhibitor.

  2. Drug

    Declopramide

    go.drugbank.com/drugs/DB06421
    Experimental

  3. Drug

    Telenzepine

    go.drugbank.com/drugs/DB19508
    Investigational

    The usage of the INN stem '-zepine' in the name indicates that Telenzepine is a tricyclic compound.

  4. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory.

  5. Drug

    Felezonexor

    go.drugbank.com/drugs/DB21067
    Investigational

    The usage of the INN stem '-nexor' in the name indicates that Felezonexor is a nuclear export inhibitor.

  6. Drug

    Edaxeterkib

    go.drugbank.com/drugs/DB21490
    Investigational

    The usage of the INN stem '-terkib' in the name indicates that Edaxeterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  7. Drug

    Ledaborbactam etzadroxil

    go.drugbank.com/drugs/DB21455
    Investigational

    The usage of the INN stem '-bactam' in the name indicates that Ledaborbactam etzadroxil is a ẞ-lactamase inhibitor.

  8. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel.

  9. Drug

    Icovamenib

    go.drugbank.com/drugs/DB21669
    Investigational

    The usage of the INN stem '-menib' in the name indicates that Icovamenib is a menin interaction inhibitor.

  10. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sa...